Do you recommend frontline bevacizumab with carbo/taxol in patients with advanced epithelial ovarian and BRCA mutation who will be receiving olaparib maintenance?
Answer from: Medical Oncologist at Academic Institution
As shown in GOG-218, there is no apparent benefit to using concurrent bevacizumab with paclitaxel and carboplatin in the first-line setting, if this drug is not then continued during maintenance therapy. Our approach is to obtain genetic testing in patients with epithelial ovarian cancer as so...
Comments
Medical Oncologist at William C Waterfield MD I don't see an issue with using Bev and olaparib i...
Medical Oncologist at Harvard Medical School In response to @William C. Waterfield's comment, I...
I don't see an issue with using Bev and olaparib i...
In response to @William C. Waterfield's comment, I...